The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Markets Update: What Investors Are Watching
How Markets Have “Changed Forever”
Markets Update: CEO David Solomon Shares His Perspectives on the Current Environment
COVID-19’s Impact on US Small Businesses
Markets Update: Do Investors Think the S&P 500 Has Bottomed Out?
Client Call: Market Volatility and Potential Economic Impacts
Markets Update: Europe and COVID-19
Update on US Growth and Earnings Forecasts, and Expected Stimulus Programs
Markets Update: How COVID-19 Is and Isn't Like the '08 Financial Crisis
Re-thinking How We Work During a Pandemic
Markets Update: The Fed's Recent Efforts to Increase Liquidity
After a Sharp Drop in Prices, What's Next for Oil?
Markets Update: March 6, 2020
How Computational Biology is Transforming Drug R&D
Markets Update: Coronavirus
From “Fish Out of Water” to Wall Street Changemaker
Markets Update: February 21, 2020
Global Market Shocks from the '87 Crash to Brexit: Lessons for Today
Markets Update: February 14, 2020
Why Investing in the Longest Bull Market in History is Still a Smart Move
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money